ClinicalTrials.gg
CompletedNCT01703624Updated Mar 30, 2016

Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of glycopyrronium bromide in Chronic Obstructive Pulmonary Disease, sponsored by Prosonix Limited. Completed at 1 site in United Kingdom. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-03-30.

Sponsored by Prosonix Limited (part of NIOX Group plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
59th of 73
37 · median 152
Started
2013
with 4 others
Phase 2
19 of 73
none open now
Registered
28th of 73
by date
Lead sponsor
1 of 73
Prosonix Limited

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 59th largest by enrollment, is one of 5 that started in 2013, is one of 19 in phase 2, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is an investigation of the beneficial effects, tolerability and safety of a range of single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female patients with moderate or severe chronic obstructive pulmonary disease (COPD). COPD is a long term and progressive disease of the lungs, generally caused by cigarette smoking, but other factors may be involved. Glycopyrronium bromide (GB) appears to be particularly useful in dilating the constricted airways of such patients, with a duration of action variously described as being between 12 and 24 hours.

This study will investigate how well tolerated and safe this medication is at a range of doses. It will also help in the selection of a suitable dose for larger and repeat dose studies, based on measures of lung response. It will also help to determine how often the medication should be given; twice daily, or once daily.

Up to 40 patients will be enrolled into the study, ranging in age from 40 to 75 years of age. Patients will be medically assessed before participation to ensure their suitability. The study will take place in one centre in the UK over five sessions; at each session one dose (2 puffs) of GB or one dose (2 puffs) of placebo will be administered from a simple inhaler device. Neither staff nor patients will know which dose, or if placebo, is being taken. Lung function will be measured for up to 26 hours after the administration of each dose using standard spirometry equipment. Blood samples will be taken over a 24-hour period to check the blood levels of GB. There will be a period of about a week between each dosing session. Patients will be medically reviewed after the study to confirm that no untoward effects are present.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • glycopyrronium bromide
  • glycopyrrolate
  • oral inhalation
  • COPD
  • chronic obstructive pulmonary disease
  • lung function
  • pharmacokinetics
  • tolerability
  • safety
  • cross-over
  • single-dose
  • dose-ranging
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 40-75 years, inclusive
  • A clinical diagnosis of moderate to severe (GOLD guidelines)
  • Current smokers or ex-smokers with at least 10-pack year smoking history
  • Post-bronchodilator /FVC ratio \< 70 % at Screen
  • Post-bronchodilator FEV1 ≥ 40 % to \< 80 % of predicted at Screen
  • Demonstrated to be responsive to ipratropium (defined as at least an 100ml increase in FEV1 following ipratropium 80 µg)
  • Ability to perform acceptable spirometry (ATS/ERS guidelines)
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or lactating at the Screening Visit, or if of not using an acceptable means of throughout the study (defined in protocol)
  • Current evidence or recent history of any disease (other than ) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data (defined in protocol)
  • Recent history of hospitalisation due to an exacerbation of airway disease within three months prior to the Screening Visit or randomisation
  • Need for increased treatments of COPD within six weeks prior to the Screening Visit or randomisation
  • Primary diagnosis of asthma
  • Prior lung volume reductions surgery or history of chest/lung irradiation
  • Regular use of daily oxygen therapy
  • Use of systemic within three months prior to the Screening Visit or during the run-in period
  • Respiratory tract infection within six weeks prior to the Screening Visit.
  • History of tuberculosis, bronchiectasis or other non-specific pulmonary disease
  • History of urinary retention or bladder neck obstructive type symptoms
  • History of narrow-angle glaucoma
  • Clinically significant abnormal
  • Positive antigen or positive antibody
  • Positive screening test for antibodies
  • Current evidence or history of excessive use or abuse of alcohol in the opinion of the Investigator
  • Current evidence or history of abusing legal drugs or use of illegal drugs or substances in the opinion of the Investigator
  • Donation of 450 ml or more of blood within eight weeks of the Screening Visit
  • History of or intolerance to aerosol medications
  • Participation in another drug study where drug was received within 30 days prior to the Screening Visit.
  • Inability to comply with study procedures or with study treatment intake, including inability to be trained and/or inability to demonstrate good inhaler technique with Vitalograph AIM
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    glycopyrronium bromide 12.5mcg

    glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)

    Drug: glycopyrronium bromide

  • Experimental
    glycopyrronium bromide 25mcg

    glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)

    Drug: glycopyrronium bromide

  • Experimental
    glycopyrronium bromide 50mcg

    glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)

    Drug: glycopyrronium bromide

  • Experimental
    glycopyrronium bromide 100mcg

    glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)

    Drug: glycopyrronium bromide

  • Placebo comparator
    placebo

    placebo single dose via pressurised metered dose inhaler (pMDI)

    Drug: glycopyrronium bromide

Interventions

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)

    FEV1 time-adjusted AUC(0-24 hours)

    Time frame: From time zero to 24-hours

Secondary outcomes

  1. Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)

    FEV1 time-adjusted AUC(0-12 hours)

    Time frame: From time zero to 12-hours

  2. Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)

    FEV1 time-adjusted AUC(12-24 hours)

    Time frame: From 12 to 24-hours

  3. Forced Expiratory Volume in one second (FEV1)

    Serial FEV1 time-point assessments

    Time frame: From time zero to 24-hours

  4. Forced Vital Capacity (FVC) Area Under the Curve (AUC)

    FVC time-adjusted AUC(0-24 hours), AUC(0-12 hours), AUC(12-24 hours), serial time-point assessment

    Time frame: From time zero to 24-hours

  5. Forced Expiratory Volume in one second (FEV1) / Forced Vital Capacity (FVC) ratio

    Serial FEV1/FVC time-point assessment

    Time frame: From time zero to 24-hours

  6. Number of subjects reporting adverse events after each treatment as a measure of safety and tolerability

    Adverse event monitoring will begin once a subject provides informed consent and will continue until study participation is concluded; incidence rates will be summarised by system organ class, preferred term, severity and by reported relationship to study drug for each treatment

    Time frame: An average of 9 weeks

  7. Systolic blood pressure

    Descriptive statistics will be presented for the serial measurements by treatment

    Time frame: From time zero to 24-hours

  8. Diastolic blood pressure

    Descriptive statistics will be presented for the serial measurements by treatment

    Time frame: From time zero to 24-hours

  9. Peripheral pulse rate

    Descriptive statistics will be presented for the serial measurements by treatment

    Time frame: From time zero to 24-hours

  10. Electrocardiography (ECG)

    Descriptive statistics will be presented for the serial measurements of each of the standard electrocardiographic (12-lead) parameters by treatment

    Time frame: From time zero to 24-hours

  11. Clinical hematology

    Clinical hematology measures will be taken at the Screening Visit and at the Safety Follow-up Visit and will consist of: red blood cell count, hemoglobin, hematocrit, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, white blood cell count, differential white blood cell count and platelet count. Data will be summarised using descriptive statistics

    Time frame: An average of 9 weeks

  12. Clinical chemistry

    Clinical chemistry measures will be taken at the Screening Visit and at the Safety Follow-up Visit and will consist of: sodium, potassium, urea, creatinine, uric acid, glucose, calcium, inorganic phosphorus, total bilirubin, alkaline phosphatase, alanine transaminase, aspartate transminase, gamma glutamyl transferase, creatine kinase, total protein, albumin, cholesterol and triglycerides. Data will be summarised using descriptive statistics

    Time frame: An average of 9 weeks

  13. Plasma glycopyrronium bromide concentration-time Area Under the Curve (AUC)

    AUC (0-infinity) will be extrapolated from serial measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

  14. Plasma glycopyrronium bromide peak concentration (Cmax)

    Cmax will be obtained from serial measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

  15. Plasma glycopyrronium bromide time to maximum concentration (tmax)

    tmax will be calculated from serial measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

  16. Plasma glycopyrronium bromide concentration elimination half-life (t1/2)

    t1/2 will be calculated from serial measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

  17. Glycopyrronium bromide total plasma clearance following extravascular administration (CL/F)

    CL/F will be calculated from serial plasma concentration measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

  18. Glycopyrronium bromide apparent volume of distribution following extravascular administration (Vz/F)

    Vz/F will be calculated from serial plasma concentration measures taken over time zero to 24-hours. The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation

    Time frame: From time zero to 24-hours

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2012
First posted
Oct 10, 2012
Start
May 2013
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Last update
Mar 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01703624
Lead sponsor
Prosonix Limited
Responsible party
Sponsor
First posted
Oct 10, 2012
Start date
May 2013
Primary completion
Aug 2013
Completion
Sep 2013
Last update
Mar 30, 2016

Study contacts

Geoff Down, MB BS FFPM
study director · Prosonix Limited, Oxford, UK
Dave Singh, MA MD MRCP
principal investigator · Medicines Evaluation Unit, Manchester, UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion